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Abstract: A novel class of transcripts, long non coding RNAs (lncRNAs), has recently 
emerged as key players in several biological processes, including dosage compensation, 
genomic imprinting, chromatin regulation, embryonic development and segmentation, stem 
cell pluripotency, cell fate determination and potentially many other biological processes, 
which still are to be elucidated. LncRNAs are pervasively transcribed in the genome and 
several lines of evidence correlate dysregulation of different lncRNAs to human diseases 
including neurological disorders. Although their mechanisms of action are yet to be fully 
elucidated, evidence suggests lncRNA contributions to the pathogenesis of a number of 
diseases. In this review, the current state of knowledge linking lncRNAs to different 
neurological disorders is discussed and potential future directions are considered. 
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1. Introduction 
For the last few decades of the 20th century, the underlying dogma of molecular biology has been 
that the purpose of RNA is to direct the assembly of proteins from amino acids. A few exceptions to 
this paradigm were known (such as ribosomal RNA and transfer RNA, which are functional RNA 
macromolecules that do not code for protein). Non-coding RNAs (ncRNAs) include the familial 
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“housekeeping” RNAs and the thousands of regulatory RNAs that are the subject of recent intense 
investigation. NcRNAs come in many different sizes and for this reason have been divided into small 
and long classes: small ncRNAs (sncRNA) being less than 200 nucleotides (nt), and long ncRNAs 
(lncRNA) greater than 200 nt to over 100 kb in length [1]. The current cut-off is arbitrary and 
corresponds to certain biochemical fractionation protocols and excludes most categories of small 
infrastructural or regulatory RNAs (tRNAs, snRNAs, miRNAs, siRNAs, piRNAs, tiRNAs, spliRNAs, 
sdRNAs and others, Figure 1).  
Figure 1. Non-coding RNAs (ncRNAs) are arbitrarily grouped basing on size. Small 
ncRNAs being less than 200 nucleotides and long ncRNAs greater than 200 nucleotides. 
 
An estimation of the number of lncRNA loci from transcriptional surveys in mammals suggests that 
they are at least as numerous as protein-coding genes [2] with many of lncRNAs identified in 
intergenic regions alone [3]. With a few exceptions, it is only within the past few years that the 
functions and mechanisms of lncRNAs have begun to emerge. 
The lncRNAs that have been studied in detail were found to be involved in different biological 
processes including X chromosome inactivation, nuclear structure, genomic imprinting and development. 
In the following paragraphs some of the known functions of lncRNAs will be discussed with 
particular regard to their role in neurological disorders. 
2. Identification of lncRNAs 
Data derived from massive cloning and traditional sequencing methods have demonstrated that 
mammalian genomes produce thousands of RNA transcripts in addition to protein-coding genes [2]. 
These studies modified our simplistic view of the genome and suggested the presence of thousands of 
previously unknown transcripts. Recently more than 3000 intergenic ncRNAs have been found in the 
mammalian genome, by using information from chromatin modifications [3,4]. Evidence gained from 
ChIP-Seq analyses demonstrated that transcribed protein-coding genes have unusual chromatin 
modifications; these modifications are trimethylation of histone H3 at lysine 4 (H3K4me3) at the 
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promoter region and trimethylation of histone H3 at lysine 36 (H3K36me3) in the body of the  
gene [5]. By eliminating these chromatin domains that correspond to protein-coding genes more than 
3000 intergenic domains transcribed into lncRNAs have been found. Bioinformatics analyses showed 
that the majority of these transcripts have no protein-coding capability. Moreover, it was shown that 
many of these lncRNAs are able to interact with multiple chromatin-modifying complexes in different 
human and mouse cell types suggesting that lncRNAs may be involved in epigenetic regulation [3].  
Recent advances in RNA sequencing technology (RNA-Seq) addressed further interrogation of the 
total cellular RNA, or, transcriptome, at a much higher resolution [6]. Thousands of transcripts, in 
addition to protein-coding mRNAs and microRNAs, have been found to be expressed in a wide range 
of tissues and cell types [7]. 
3. Epigenetics 
Many of the lncRNAs seem to be involved in epigenetic mechanisms of gene regulation. Although 
the field of epigenetics earned its name over 50 years ago, just in this past decade the significance of 
epigenetics has been recognized in human health and disease [8]. The term epigenetics refers to 
changes in gene expression and/or phenotype that can be heritable without a change in the underlying 
DNA sequence. Several factors contribute to epigenetic mechanisms of gene regulation including 
DNA methylation, histone modifications, and ncRNAs. DNA methylation in the promoter region of 
genes is typically associated with transcriptional repression. Several mammalian enzymes are 
responsible for establishing and maintaining DNA methylation in the genome [9]. 
The modification of histone proteins has also been found in epigenetic regulation [10]. Histones are 
highly conserved proteins that package DNA in the nucleus and modulate the accessibility of 
transcription factors and RNA polymerases to DNA. Histone modifications typically take place at 
amino acids located in the N-termini of histones such as lysine, arginine and serine residues that can be 
acetylated or methylated (lysine and arginine) and phosphorylated (serine). Histone modifications are 
placed on and removed from histone residues by numerous enzymes that usually work as part of  
multi-protein complexes [10]. 
A relevant question in biology is how chromatin-modifying complexes are targeted to specific 
genomic loci since many of these enzymes lack DNA binding capacity. Recent studies suggest a 
potential role for ncRNA in driving chromatin-modifying complexes to genomic loci [11–13], 
however, the exact mechanism by which ncRNAs drive complexes is not known and is currently  
under investigation. 
4. Functions of lncRNAs 
Basing on our current knowledge of lncRNAs, it appears that such molecules are involved in many 
different aspects of cellular functions (reviewed in [14,15]). The roles of lncRNAs in the regulation of 
gene expression and organismal development are different and just beginning to be discovered. 
Biological processes dependent upon lncRNAs include imprinting and gene dosage regulation, stem 
cell pluripotency, embryonic development and segmentation, hematopoiesis, and neural cell fate 
determination (see for review ref [16]). LncRNAs may employ a number of mechanisms to impact 
gene expression via cis and trans processes. 
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4.1. Gene Imprinting 
While the function of parental gene imprinting is still unclear, lncRNAs have been found to 
participate in imprinting processes. These are referred to as the events that influence the monoallelic 
expression of a gene according to its parents of origin. Imprinting control regions (ICRs) are DNA 
regions that are differentially methylated depending on their parental origins. Unmethylated ICRs 
cause specific expression of nearby lncRNAs, which then suppress neighboring genes in cis. Several 
imprinted clusters contain protein-coding genes and lncRNAs that are reciprocally expressed, such as 
IGf2r/Air [17], Dlk1/Gtl2 [18,19], and Nesp/Nespas/Gnas [20]. Some of these lncRNAs can exert their 
function by recruiting epigenetic factors, such as PRC2 and G9a, in order to control the imprinted 
expression of neighboring coding genes [21,22].  
Airn and Kcnq1ot1 are examples of lncRNAs that cause suppression of paternally inherited genes. 
Kcnq1ot1, in particular, is involved in the repression of several protein-coding genes in cis through 
interaction with repressive chromatin modifying complexes [23,24]. 
H19 was one of the first mammalian lncRNAs to be identified and is highly expressed in the 
embryo [25,26]. Though it does not seem to act as an lncRNA [27], H19 likely functions as an miRNA 
precursor [28,29] and is mutually imprinted with the protein-coding gene Igf2. 
4.2. Gene Dosage and X Chromosome Inactivation 
The X chromosome inactivation (XCI) indicates the mechanisms by which the difference in  
X-linked gene dosage between XX females and XY males is exerted in therian mammals in which one 
of the two X chromosomes in females is silenced (the inactive X or Xi) so that only one X remains 
active and is expressed in each female cell (the active X, or Xa) [30]. It is well-known that XCI in 
placental mammals is largely controlled by a cluster of lncRNA loci known as the X-inactivation 
center (Xic) [31]. The X (inactive)-specific transcript (Xist) is highly expressed from Xi during the 
onset of XCI but not from Xa, contributing a defining moment for the realization that lncRNAs can 
have profound roles in the control of gene expression even though the exact mechanism of action is 
still not completely understood. Some evidence suggests that Xist mediates the chromosome X 
silencing effects by interacting with repressive chromatin-modifying complexes such as PRC2 [22]. 
Xist itself is also regulated by other lncRNAs. Initially, Xist and Tsix, its antisense transcript, 
transcribed from a promoter downstream of Xist, are expressed on both X chromosomes. However, 
Tsix expression continues on the X that will remain active (Xa) and this activity recruits dnmt3a to 
suppress Xist from being transcribed on Xa [32]. Conversely on Xi, it is Tsix that is suppressed, 
potentially through another lncRNA that is part of the X inactivation center, Jpx [33]. With Tsix 
suppressed, the protein PRC2 is recruited to induce histone modification marks at the 5' end of Xist. 
This upregulates Xist expression on Xi and causes further propagation of these silencing marks 
throughout Xi, which are maintained across the lifetime of the organism [33]. 
4.3. Embryonic Development and Segmentation 
LncRNAs are likely implicated in processes involving animal development. The Hox genes encode 
homeodomain TFs that are crucial for anterior-posterior pattern formation in bilateral metazoans [34]. 
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Hox genes are structured in linear clusters along the chromosome, and mammals have four paralogous 
clusters, HoxA, -B, -C, and -D. Several lncRNAs are encoded within these clusters, including HOTAIR 
(Hox antisense intergenic RNA) from HoxC, and HOTTIP and Mistral from HoxA [35–37]. The 
expression of Hox genes is also regulated by lncRNAs [36]. Some Hox-related lncRNAs operate in cis, 
having either enhancing or repressive effects. However, some like the human HOTAIR  
works in trans, and it is expressed from the Hox locus marking a boundary of active and inactive 
chromatin [35]. Furthermore, HOTAIR, similar to Xist, interacts with chromatin-modifying complexes 
such as PRC2 and the corepressor complex CoREST [35] and may guide these complexes to genomic 
loci. Overexpression of HOTAIR caused cells to become metastatic when injected into mice compared 
to control cells with an empty vector. Moreover, HOTAIR may serve as a scaffold for targeting 
chromatin-modifying complexes to chromatin [35].  
Recently HOTAIR was found to be crucial for cell growth and viability and that its knockdown 
induced apoptosis in breast cancer cells Moreover it was found that HOTAIR is transcriptionally 
induced by estradiol [38]. It is possible that other lncRNAs that interact with chromatin-modifying 
complexes also function in a manner similar to HOTAIR. 
4.4. Stem Cell Pluripotency and Cell Fate Determination  
The promoters of more than 100 lncRNAs are bound by stem cell factors. Disruption of these 
lncRNAs can alter cell differentiation. The human lncRNA-RoR (RoR) is a recently identified lncRNA 
that is capable of reprogramming differentiated cells to induce pluripotent stem cells [39,40]. RoR is 
highly expressed both in embryonic stem cells and in induced pluripotent stem cells, due to the 
regulation of RoR by pluripotency transcription factors such as Oct4, Sox2 and Nanog. Interestingly it 
was observed that knockdown of RoR leads to a modest increase in apoptosis and activation of p53 
pathways [40]. Although the underlying mechanisms still remain to be fully clarified, Zhang et al. 
recently [41] demonstrated that human RoR is a strong negative regulator of p53 influencing the 
inhibition of p53-mediated cell cycle arrest and apoptosis. 
Recently, a refined analysis from Guttman et al. [39] performed loss-of-function studies on 226 
lncRNAs expressed in mouse embryonic stem cells characterizing the effects on gene expression. The 
authors identified 26 lncRNAs able to maintain the pluripotent status. In particular, knockdown of 
these lncRNAs resulted in a loss of pluripotency markers, and reduction of Nanog promoter activity. 
Simultaneously, expression patterns similar to differentiation into specific lineages were produced, 
suggesting that lncRNAs repressed differentiation programs in mouse embryonic stem cells. 
Altogether these findings support the hypothesis that some lncRNAs are integral members of a 
regulatory network, together with key pluripotent transcription factors, which modulate pluripotency 
and lineage-specific differentiation pathways in mouse embryonic stem cells.  
lncRNAs are implicated in cell fate determination events in multiple cells lineages, including the 
nervous system. Taurine upregulated gene 1 (TUG1) is an lncRNA expressed in the developing retina 
and brain, as well as in adult tissues. It has been found that in the newborn retina, loss of TUG1 
resulted in malformed or non-existent outer segments of transfected photoreceptors, thus suggesting 
that TUG1 is required for the proper formation of photoreceptors in the developing rodent retina [42]. 
Evf2 is instead a mouse lncRNA that appears to recruit Dlx and Mecp2 transcription factors to 
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important DNA regulatory elements in the Dlx5-Dlx6 intergenic regions and controlled Dlx5, Dlx6 and 
Gad1 expression through cis and trans acting mechanisms. Evf2 mouse mutants appeared to have 
reduced numbers of GABAergic interneurons in early postnatal hippocampus and the dentate gyrus. 
This situation is restored to normality in Evf2 mutant adult hippocampus although reduced synaptic 
inhibition still occurred [43,44]. 
Although many lncRNAs have been shown to regulate gene expression only a few have been shown 
to have other cellular functions. For example, NEAT1 has been shown to play an important role in 
paraspeckle formation [45]. Also NRON has a role in nuclear import/export [46]. All together, these 
studies suggest that the lncRNAs have different cellular functions, many of which are yet to be 
identified and characterized for the mechanism of their function. 
5. LncRNAs in Human Diseases 
As the functions and mechanisms of lncRNAs are beginning to emerge, there is an intense interest 
in identifying any potential role of these molecules in human diseases. Several studies have shown that 
lncRNAs are dysregulated in human pathologies, however it has yet to be shown that these molecules 
are enough to drive the disease status. 
lncRNAs have been strongly associated with cancer [47]. Recently, the lncRNA PCAT-1, was 
found to promote cell proliferation and is a target of PRC2 regulation, [48]. Moreover, ANRIL, which 
is upregulated in prostate cancer, is required for the expression of the tumor suppressors INK4a/p16 
and INK4b/p15 [49]. HOTAIR upregulation is associated with poor prognosis in breast cancer [11], 
liver [50], colorectal [51], gastrointestinal [52] and pancreatic [53] cancers and probably contributes to 
increase also tumor invasiveness and metastasis [11].  
MALAT-1, which is another lncRNA associated with various cancers and metastasis [54] was 
found to affect the transcriptional and post-transcriptional regulation of cytoskeletal and extracellular 
matrix genes [55]. Although lncRNAs have been extensively investigated in cancers several lines of 
evidence suggest a possible role also in different disease conditions such as cardiovascular diseases. 
For example, two lncRNAs have been found to be dysregulated in heart disease; the expression of the 
lncRNA MIAT is associated with increased risk of myocardial infarction, whereas the lncRNA ANRIL 
is associated with increased risk to coronary heart disease [56,57]. Recently, a novel lncRNA has been 
discovered, named DBE-T, that functions in cis and localizes to the Facioscapulohumeral muscular 
dystrophy (FSHD) locus. FSHD is the third most common myopathy and is predominantly caused by a 
contraction of specific repeats mapping on chromosome 4q35 [58]. It is suggested that DBE-T likely 
acts as a locus control element by promoting active chromatin domains and thus FSHD would be 
caused from lncRNA “promoter mutations” able to perturb DBE-T regulation [58]. Furthermore, a 
novel lncRNA seems to be involved in the pathogenic mechanisms underneath the HELLP syndrome 
(hemolysis, elevated liver enzymes, low platelets) that is a recessively inherited life-threatening 
pregnancy complication [59]. 
6. Role of lncRNAs in the Central Nervous System 
Recent evidence demonstrate that lncRNAs contribute to the complex biological system 
organization and gene regulatory networks of the central nervous system (CNS), affecting brain 
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patterning, neural stem cell maintenance, neurogenesis and gliogenesis, stress responses, and synaptic 
and neural plasticity.  
Mercer and colleagues identified 849 lncRNAs (among the 1328 examined), that are expressed in 
the adult mouse brain and found that the majority were associated with specific neuroanatomical 
regions, cell types, or subcellular compartments [60]. A complementary study showed that over 200 of 
these lncRNAs are expressed in developing and adult mouse brain and are largely derived from genomic 
loci located proximal to protein-coding genes with similar expression profiles in the brain [61]. 
Guttman et al. discovered more than 1000 evolutionarily conserved intergenic lncRNAs in mouse 
by analyzing chromatin signatures from four mouse cell types [5]. A functional analysis of the 
expression of these lncRNAs revealed the presence of a “brain cluster” of lncRNAs that is associated 
with biological processes including hippocampal development, oligodendrocyte (OL) myelination, 
brain aging, CREB and PGC1-alpha transcriptional regulation, and GABAergic neuronal (GABAN),  
G protein coupled receptor and calcineurin signaling pathways. An additional study demonstrated  
that 169 lncRNAs are differentially expressed during the sequential processes of mouse ventral  
forebrain-derived neural precursor cells mediated lineage restriction, GABAN and OL lineage 
specification, progressive OL lineage maturation, and terminal differentiation including myelination [62].  
Detailed analyses of specific lncRNAs, dynamically expressed in the CNS, reveal potential roles in 
mediating neural cell fate decisions. The Sox2OT lncRNA, which contains the Sox2 gene within one of 
its introns and is subsequently transcribed in the same direction [63], is expressed in regions of 
constitutive adult neurogenesis [60]. Moreover, Sox2OT is dynamically regulated in CNS structures 
during development, where it may be responsible for modulating Sox2 expression [64]. The lncRNA 
Nkx2.2AS regulates Nkx2.2, a transcription factor that is critical for OL lineage specification. A recent 
study reported that forced expression of Nkx2.2AS in NSCs in vitro enhances their differentiation 
along the OL lineage, in part, by inducing an increase in Nkx2.2 mRNA levels [65].  
LncRNAs also modulate synaptic plasticity and promote long-term changes in synaptic strength. 
The rodent-specific BC1 and primate-specific BC200 lncRNAs, are selectively targeted to postsynaptic 
dendritic compartments, where they regulate local protein synthesis by repressing the initiation of 
translation through an eIF4A-dependent mechanism [66–69]. Similarly, NTAB is a lncRNA that is 
expressed in developing and adult rat brain, where it is also found in neuronal processes [70]. Another 
lncRNA, MALAT-1, is enriched in hippocampal neurons, where it regulates several serine/arginine 
splicing factors important for synapse formation, density and maturation [71]. 
6.1. Dysregulation of lncRNAs in Neurological Disorders 
6.1.1. LncRNAs Play a Role in the Pathophysiology of Several Neurological Disorders 
Angelman syndrome (AS) is a neurodevelopmental disorder associated with genomic imprinting 
and characterized by severe neurologic abnormalities [72]. Ube3a-as is a lncRNA transcribed antisense 
to the maternally expressed Ube3a gene, mutated or deleted in AS, suggesting that Ube3a-as may 
repress paternal Ube3a expression. Other studies have shown that repression of Ube3a is dependent on 
Ube3a-as [73,74]. However, other data has demonstrated that silencing of paternal Ube3a can occur in 
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the absence of Ube3a-as and implies a more complex regulatory relationship underlying the imprinting 
of Ube3a [75].  
LncRNAs may influence the pathogenesis of fragile X syndrome (FXS), which is characterized by a 
triplet nucleotide repeat expansion in the 5'UTR of FMR1, the gene encoding the neuronal 
development protein, FMRP. The lncRNAs ASFMR1 and FMR4 are generated from the FMR1 gene 
locus. ASFMR1 has multiple alternative splicing patterns and overlaps the 5' untranslated region 
(UTR) CGG repeat region of FMR1 [76]; FMR4 is initiated upstream of the FMR1 start site. 
Alternative splicing of ASFMR1 seems to exhibit pre-mutation-specific profiles and is also silenced in 
FXS patients and upregulated in pre-mutation carriers, suggesting that a common process is 
responsible for regulating the expression of these transcripts. FMR4 is also silenced in FXS patients 
because of a CGG expansion repeat in the 5'UTR of the FMR1 gene and upregulated in pre-mutation 
carriers [77]; thus, their absence in the neurons of affected patients might contribute to the 
pathogenesis of this neurological disorder.  
Another microsatellite expansion disease in which lncRNAs are involved is the spinocerebellar 
ataxia type 8 (SCA8), an autosomal dominant disorder, characterized by bidirectional transcription of 
this expansion repeat from opposite strands, forming both a protein-coding transcript encoding a 
polyglutamine expansion, ATXN8, and a lncRNA transcript containing a CUG expansion,  
ATXN8OS [78]. This suggests that SCA8 pathogenesis involves a toxic gain of function at both the 
protein and RNA levels. A recent study found that the expanded ATXN8OS transcript accumulates in 
ribonuclear inclusions in the GABAergic neurons of SCA8 patients [79]. These inclusions co-localized 
with splicing factor, MBNL1, altering the activity of MBNL alternative splicing proteins [79]. 
Huntington’s disease (HD) is caused by an expansion repeat mutation in the Htt gene, which 
encodes a ubiquitously expressed 3144 amino acid protein of unknown function, leading to a toxic 
gain of function in the mutant protein [80], which promotes aberrant nuclear-cytoplasmic trafficking of 
the master neuronal regulator REST. The result is the deregulation of REST target gene expression in 
tissues from animal models of HD and human HD, which include both protein-coding genes as well  
as ncRNAs, such as lncRNAs. It is therefore likely that HD tissues are also characterized by 
dysregulation of lncRNA expression. ChiP-seq data showed that the HAR1 locus is under control of  
REST [81]. The HAR1 region contains lncRNAs, HAR1F and HAR1R. HAR1F is specifically 
expressed in the neurons of the marginal zone during development of the cortex and in the frontal 
cortex, hippocampus, cerebellum, thalamus and hypothalamus in the adult brain [82]. The levels of 
HAR1F and HAR1R are decreased in HD brains compared with normal brains [83].  
6.1.2. LncRNAs in Neurodegenerative Diseases, such as Alzheimer’s Disease (AD)  
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is a crucial enzyme in AD 
pathophysiology, involved in the cleavage of the amyloid precursor protein (APP) and the generation 
of amyloid peptides which can aggregate and form plaques. Faghihi and colleagues characterized a 
conserved non-coding antisense transcript for BACE1, called BACE1-AS, which functions as a 
regulator of BACE1 gene expression. BACE1-AS upregulates BACE1 levels in response to a variety 
of stresses, including Aβ 1–42 exposure, and is elevated in several brain regions of patients with AD. 
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These findings imply that BACE1-AS is deregulated in AD, which induces feed-forward regulation of 
BACE1, increases Aβ levels, and thus may promote the pathogenesis of the disease [84].  
Mus et al. found a link between altered levels of a lncRNA, BC200, and AD [85]. Increased levels 
of BC200 were found in brain regions that are preferentially affected in AD, such as the hippocampus, 
which correlated with disease severity. Further, in advanced stages of AD, BC200 was mis-localized 
and clustered in the perikaryon. These observations suggest that deregulation of this synaptic lncRNA 
is involved in the synaptic and neural network dysfunction that is found in both early and later stages 
of AD [85]. 
Together with neurological diseases, a number of psychiatric disorders have also been associated 
with lncRNAs (Table 1). The risk of developing schizophrenia (SZ), schizoaffective disorder, bipolar 
disorder, major depression, and autistic spectrum disorders has been linked to the disruption of the 
DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA [86–88]. 
DISC2 controls the expression of its partner, DISC1, which modulates multiple aspects of CNS 
structure and function such as embryonic and adult neurogenesis [89]. Another lncRNA, Gomafu, 
implicated in brain and retinal development [62,90] binds directly to the splicing factors QKI and 
SRSF1 and the dysregulation of Gomafu induces alternative splicing that resemble those observed in 
SZ for the archetypal SZ-associated genes DISC1 and ERB4. Moreover, Gomafu is downregulated in 
post-mortem cortex of SZ subjects, suggesting a role in SZ pathogenesis for this lncRNA [91]. 
Table 1. Examples of lncRNAs that are dysregulated in neurological disorders. 
lncRNA Disease association Biological function Reference
Ube3a-as Angelman Syndrome Repress paternal Ube3a expression [72] 
ASFMR1 FMR4 Fragile X Syndrome Regulate the expression of ASFMR1 
and FMR1 genes 
[76,77] 
ATXN8OS SCA8 Alteration of the activity of  
the splicing factor MBNL1 
[78,79] 
HAR1F HAR1R Hungtington’s Disease Influence genes promoting aberrant 
nuclear-cytoplasmatic trafficking  
of REST gene 
[83] 
BC200 BACE1-AS Alzheimer’s Involved in the synaptic and  
neural network dysfunction  
Regulates BACE1 gene expression 
[84,85] 
DISC2 Gomafu Psychiatric disorders Controls the expression of DISC1  
Implicated in brain  
and retinal development 
[86–89]  
[91] 
7. Conclusions and Future Perspectives  
Several recent studies suggest that lncRNAs play a pivotal role in many key biological processes, 
although their mechanisms of action are yet to be fully elucidated. Currently there is great interest in 
identifying the functions of this novel class of transcripts. There is strong evidence that many lncRNAs 
are biologically relevant, with a large percentage of these molecules functioning through their 
interactions with chromatin-modifying complexes to alter gene expression [3]. These findings are 
beginning to shed light on how chromatin-modifying complexes are targeted to specific genomic loci 
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and suggest the interesting idea that lncRNAs are in some way driving chromatin-modifying 
complexes to genomic loci.  
LncRNAs have, in a relatively short period of time, become recognized as a major new class of 
genes that may potentially comprise a major component of the genome’s information content, 
complementary and comparable in abundance and complexity to the proteome. Furthermore lncRNAs 
have already been reported in a wide range of human diseases suggesting that their activity is crucial 
for human health. 
In addition, therapeutic strategies that target endogenous mRNA molecules, such as those 
employing RNA interference (RNAi) and other customized oligonucleotide approaches with the 
capacity to reprogram disease-associated mRNAs, are now being developed [92]. These approaches 
could be adapted to target lncRNAs whose expression is dysregulated in CNS disorders. These 
observations suggest that lncRNAs represent a versatile class of factors that are centrally important to 
the modulation of different CNS processes and may represent a major layer underlying the genetic 
programming of brain development that could potentially be utilized for developing novel diagnostic 
and therapeutic tools for the cure of CNS disorders. 
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